Episode 98
On this week’s Biotech Hangout, Chris Garabedian, Josh Schimmer, Tim Opler and John Maraganore discuss how it’s been a big year for PIPEs and some of the controversy that has come along with it. The hosts also open up a discussion on supply and demand of venture capital and then pivots to Genentech ending its strategic collaboration with Adaptimmune. The group discusses other deals and financings of the week including Future Pak’s proposal to acquire Vanda Pharmaceuticals, Sanofi’s plans to divest Amuniz Pharmaceuticals and Regeneron enters venture investing with a $500 million fund. The hosts also discuss data readouts from Ultragenyx, Biohaven, Sage, Cerevel/Abbvie, Eli Lilly, Roche and Novartis. The show closes out with the latest on WuXi and the impact on biotech, Humira biosimilars grabbing huge market shares and Baker Brothers returns $10 billion to investors. *This episode aired on April 19, 2024.
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.